Efficacy and Renal Safety of Dapagliflozin in Patients with Type 2 Diabetes Mellitus Also Receiving Metformin: A Real-Life Experience
Table 1
Baseline demographics and characteristics.
Characteristic
DAPA + MET alone ()
DAPA + MET + other glucose-lowering drugs ()a
Total ()
Age (years)
57.1 ± 9.3
55.1 ± 8.6
56.3 ± 9.0
Female, (%)
14 (37.8)
12 (41.4)
26 (39.4)
Weight (kg)
91.6 ± 17.9
94.6 ± 17.6
93.0 ± 17.7
Waist circumference (cm)
111.0 ± 15.0
119.0 ± 16.2
114.5 ± 15.9
Disease duration (years)
8.1 ± 5.0
11.6 ± 8.5
9.7 ± 6.9
Systolic BP (mmHg)
138.6 ± 18.5
134.7 ± 14.0
136.8 ± 16.6
Diastolic BP (mmHg)
81.5 ± 9.3
81.0 ± 12.6
81.3 ± 10.8
HbA1c (%)
8.8 ± 1.6
9.7 ± 1.5
9.2 ± 1.6
BMI (kg/m2)
33.1 ± 6.2
33.8 ± 6.3
33.4 ± 6.1
Creatinine (μmol/L)
75.1 ± 17.6
76.3 ± 15.5
75.6 ± 18.2
Microalbumin (μg/mg)
119.5 ± 139.6
67.1 ± 80.6
96.5 ± 118.6
eGFR (mL/min)
95.9 ± 29.1
96.6 ± 24.1
95.5 ± 29.7
All values are presented as mean ± standard deviation unless otherwise stated. BMI, body mass index; BP, blood pressure; DAPA, dapagliflozin; eGFR, estimated glomerular filtration rate; HbA1c, glycosylated hemoglobin; MET, metformin. aAdditional glucose-lowering agents included glimepiride or insulin. versus DAPA + MET alone.
